The FDA approved a version of the t:slim insulin pump made by Tandem Diabetes Care (NSDQ:TNDM) with an integrated G4 Platinum continuous glucose monitor made by Dexcom Inc. (NSDQ:DXCM), the companies said today.
Shipments of the t:slim G4 insulin pump are expected to begin in October, they said.
“The t:slim G4 pump combines our intuitive touch-screen interface and bright color display with Dexcom’s CGM technology, giving the diabetes community a powerful new tool to help simplify therapy management,” Tandem president & CEO Kim Blickenstaff said in prepared remarks. “CGM integration has been 1 of the most requested features since the launch of the t:slim Pump. The addition of t:slim G4 to our product family allows us to address a wider variety of diabetes management needs through the broadest range of insulin pump options available from one company.”
“We believe the t:slim G4 pump’s touch screen technology and simple user interface are a great combination for Dexcom G4 Platinum CGM integration,” added DexCom strategy & corporate development executive vice president Steve Pacelli. “CGM integration is key to future automated insulin delivery technology, and we are pleased to be working with a company like Tandem who is continuously innovating to make diabetes technology simpler to use for people with diabetes.”
Tandem announced the deal with DexCom back in July, when it also beat expectations with its 2nd-quarter results. Last month, DexCom won FDA pre-market approval for its G5 mobile CGM, the 1st approved monitor to send data directly to smartphones without a separate receiver.